IN8bio has filed a notice of an exempt offering of securities to raise $12,379,983.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, IN8bio is raising up to $12,379,983.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Tai-Wei Ho played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About IN8bio
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
To learn more about IN8bio, visit http://www.in8bio.com/
IN8bio Linkedin Page: https://www.linkedin.com/company/in8bio/
Contact:
Tai-Wei Ho, Chief Executive Officer
646-600-6438
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.